Table 1.
Classification | Compound Name | CC50a (μM) | Inhibition of SARS-CoV-2 in vitro (μM) |
||
---|---|---|---|---|---|
100% CPE Inhibitory Concentration (CPEIC100)b | 50% Reduction in Infectious Virus (EC50)c | 50% Reduction in Viral RNA Copy (EC50)d | |||
Target Compound | Cyanorona-20 | >100 | 1.40 | 0.45 | 0.48 |
Reference Compounds | Favipiravir | >100 | 98.82 | 94.09 | >100 |
Remdesivir | >100 | 22.50 | 20.17 | 23.88 | |
HCl-Arbidol-H2O | >100 | 81.52 | 64.20 | 68.42 | |
Hydroxychloroquine Sulfate | 93.06 | >100 | >100 | >100 |
CC50 or 50% cytotoxic concentration is the concentration of the tested compound that kills half the cells in an uninfected cell culture. CC50 was determined with serially-diluted compounds in Vero E6 cells at 48 h postincubation using CellTiter-Glow Luminescent Cell Viability Assay (Promega).
CPEIC100 or 100% CPE inhibitory concentration is the lowest concentration of the tested compound that causes 100% inhibition of the cytopathic effects (CPE) of SARS-CoV-2 virus in Vero E6 cells under increasing concentrations of the tested compound at 48 h postinfection. Compounds were serially 2-fold or 4-fold diluted from 100 μM concentration.
EC50 or 50% effective concentration is the concentration of the tested compound that is required for 50% reduction in infectious SARS-CoV-2 virus particles in vitro. EC50 is determined by infectious virus yield in culture supernatant at 48 h postinfection (log10 TCID50/mL).
EC50 or 50% effective concentration is the concentration of the tested compound that is required for 50% reduction in SARS-CoV-2 viral RNA copies in vitro. EC50 is determined by viral RNA copies number in culture supernatant at 48 h postinfection (log10 RNA copies/mL).